Alliance/HMR LiquiVent pivotal trial in adult acute respiratory failure to begin by mid-year.
Executive Summary
ALLIANCE/HMR LIQUIVENT ADULT PIVOTAL TRIAL TO BEGIN BY MID-1997 in adults with acute hypoxemic respiratory failure, San Diego-based Alliance predicted. Hoechst Marion Roussel is collaborating with Alliance on the development of LiquiVent (perflubron), an oxygen-carrying liquid for what Alliance terms "partial liquid ventilation," in which LiquiVent is administered "directly into the lungs of a patient who is being supported by a mechanical ventilator." HMR will market LiquiVent; the collaboration is worth up to $100 mil. to Alliance ("The Pink Sheet" March 11, 1996, T&G-10).